Cabozantinib Improves PFS Over Sunitinib in Untreated Advanced RCC

Article

A phase II trial found that cabozantinib offers significantly better progression-free survival over sunitinib in patients with untreated advanced RCC.

A randomized phase II trial found that cabozantinib offers significantly better progression-free survival (PFS) over sunitinib in patients with previously untreated advanced renal cell carcinoma (RCC), according to an announcement from the drug’s manufacturer, Exelixis. Cabozantinib was recently approved in the United States for previously treated advanced RCC.

The open-label CABOSUN trial included 157 RCC patients randomized to either cabozantinib 60 mg once daily (79 patients) or sunitinib 50 mg once daily (78 patients). All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, and all were considered intermediate- or poor-risk.

Though detailed results are not yet available, the company reported that the trial has met its primary endpoint, with a significant and “clinically meaningful” improvement in PFS with cabozantinib compared with sunitinib.

“The positive outcome of CABOSUN is extremely exciting, as it marks the very first time that a therapy has shown a PFS benefit over standard-of-care first-line treatment sunitinib for patients with previously untreated advanced RCC,” said Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and chair of the CABOSUN study, in a press release. “Based on these findings, cabozantinib may have the potential to become a new gold standard for previously untreated patients following their diagnosis with advanced kidney cancer.”

Cabozantinib is a multi-targeted tyrosine kinase inhibitor, with activity against MET; AXL; and VEGFR-1, -2, and -3. The US Food and Drug Administration granted approval for cabozantinib in April of this year, for treatment of advanced RCC in patients who had received prior antiangiogenic therapy.

That approval was based on results of the phase III METEOR trial, which compared cabozantinib with everolimus. METEOR was an open-label study that included 658 patients, and showed a 42% reduction in the rate of disease progression, as well as an improved objective response rate. The median overall survival was also better, at 21.4 months with cabozantinib compared with 16.5 months with sunitinib. Common adverse events included diarrhea, fatigue, and nausea, and 60% of cabozantinib patients required a dose reduction, compared with 24% of everolimus patients.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content